Hypertrophic Cardiomyopathy Forecast In 26 Major Markets 2018-2028 - ResearchAndMarkets.com

DUBLIN--()--The "Hypertrophic Cardiomyopathy Forecast In 26 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Hypertrophic cardiomyopathy (HCM) is a disease that contains an autosomal dominant inheritance pattern and is a moderately common transmitted genetic disease. The disease, characterised by hypertrophy in the left ventricle, cannot be explained by the presence of other clinical symptoms, such as hypertension.

This report provides the current prevalent population for HCM across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Austria, Switzerland, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort.

Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of HCM. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of HCM have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HCM include:

  • Chronic heart failure
  • Angina pectoris
  • Atrial fibrillation
  • Tachycardia

Key Topics Covered:

  1. List Of Tables And Figures
  2. Introduction
  3. Cause Of The Disease
  4. Risk Factors & Prevention
  5. Diagnosis Of The Disease
  6. Variation By Geography/Ethnicity
  7. Disease Prognosis & Clinical Course
  8. Key Comorbid Conditions / Features Associated With The Disease
  9. Methodology For Quantification Of Patient Numbers
  10. Top-Line Prevalence For Hypertrophic Cardiomyopathy
  11. Features Of Hypertrophic Cardiomyopathy Patients
  12. Genetic Background
  13. Parameters And Symptoms
  14. Comorbidities Of Hypertrophic Cardiomyopathy Patients
  15. Abbreviations Used In The Report
  16. Other Publisher Services & Solutions
  17. Reports & Publications
  18. Online Epidemiology Databases
  19. Online Pharmaceutical Pricing Database
  20. References
  21. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/k9p6k5/hypertrophic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs